

What is claimed is:

1. A method of modulating angiogenesis,
comprising administering an amount of a prokineticin
receptor antagonist effective to alter one or more indicia
5 of angiogenesis, wherein said antagonist comprises an amino
acid sequence at least 80% identical to amino acids 7 to
77 of SEQ ID NO:3, said sequence comprising;
 - (a) the 10 conserved cysteine residues of
SEQ ID NO:3, and
 - 10 (b) from 0 to 9 of amino acids 78 to 86 of
SEQ ID NO:3,
wherein amino acids 1 to 6 of said antagonist do
not consist of amino acids AVITGA (SEQ ID NO:21).
2. The method of claim 1, wherein said antagonist
15 comprises 6 or more amino acids N-terminal to the first
conserved cysteine residue.
3. The method of claim 1, wherein said antagonist
comprises 7 or more amino acids N-terminal to the first
conserved cysteine residue.
- 20 4. The method of claim 3, wherein said 7 or more
amino acids are MAVITGA (SEQ ID NO:23).
5. The method of claim 4, wherein said antagonist
comprises SEQ ID NO:18.
- 25 6. The method of claim 5, wherein said antagonist
consists of SEQ ID NO:18.

7. The method of claim 2, wherein said 6 or more amino acids are MVITGA (SEQ ID NO:39).

8. The method of claim 7, wherein said antagonist comprises SEQ ID NO:20.

5

9. The method of claim 8, wherein said antagonist consists of SEQ ID NO:20.

10. The method of claim 1, wherein said antagonist comprises 5 or fewer amino acids N-terminal to said first conserved cysteine residue.

11. The method of claim 10, wherein said 5 or fewer amino acids are VITGA (SEQ ID NO:22).

12. The method of claim 11, wherein said antagonist comprises SEQ ID NO:16.

15 13. The method of claim 12, wherein said antagonist consists of SEQ ID NO:16.

14. The method of claim 1, wherein amino acid residues that differ from residues 7 to 77 of SEQ ID NO:3 are conservative substitutions thereof.

15. The method of claim 1, wherein amino acid residues that differ from residues 7 to 77 of SEQ ID NO:3 consist of the corresponding residues from SEQ ID NO:6.

16. The method of claim 1, wherein said antagonist comprises amino acids 7 to 77 of SEQ ID NO:3.

17. The method of claim 1, wherein said antagonist is administered to an endothelial cell.

18. The method of claim 1, wherein said one or more indicia of angiogenesis comprises altered cell migration.

19. The method of claim 1, wherein said one or more indicia of angiogenesis comprises altered cell survival.

20. The method of claim 1, wherein said one or more indicia of angiogenesis comprises altered cell morphology.

21. The method of claim 1, wherein said antagonist is administered to a tissue.

22. The method of claim 21, wherein said tissue is any of cornea, chick chorioallantoic membrane and tumor tissue.

23. The method of claim 1, wherein said antagonist is administered to an animal.

24. The method of claim 23, wherein said animal is any of chicken, non-human primate, rat, mouse and human.

25. The method of claim 24, wherein said animal is a human.

26. The method of claim 23, wherein said antagonist is administered to an animal having an angiogenesis-dependent disease.

27. The method of claim 26, wherein said angiogenesis-dependent disease is cancer.

28. A method of modulating angiogenesis,
5 comprising administering an amount of a prokineticin
receptor antagonist effective to alter one or more indicia
of angiogenesis, wherein said antagonist comprises an amino
acid sequence at least 80% identical to amino acids 7 to
77 of SEQ ID NO:6, said sequence comprising;
10 (a) the 10 conserved cysteine residues of
SEQ ID NO:6, and
(b) from 0 to 4 of amino acids 78 to 81 of
SEQ ID NO:6,
wherein amino acids 1 to 6 of said antagonist do
15 not consist of amino acids AVITGA (SEQ ID NO:21).

29. The method of claim 28, wherein said antagonist comprises 6 or more amino acids N-terminal to the first conserved cysteine residue.

30. The method of claim 28, wherein said
20 antagonist comprises 7 or more amino acids N-terminal to the first conserved cysteine residue.

31. The method of claim 30, wherein said 7 or more amino acids are MAVITGA (SEQ ID NO:23).

32. The method of claim 31, wherein said
25 antagonist comprises SEQ ID NO:18.

33. The method of claim 28, wherein said antagonist comprises 5 or fewer amino acids N-terminal to said first conserved cysteine residue.

34. The method of claim 33, wherein said 5 or fewer amino acids are VITGA (SEQ ID NO:22).

35. The method of claim 29, wherein said 6 or more amino acids are MVITGA (SEQ ID NO:39).

5

36. The method of claim 28, wherein amino acid residues that differ from residues 7 to 77 of SEQ ID NO:6 are conservative substitutions thereof.

37. The method of claim 28, wherein amino acid
10 residues that differ from residues 7 to 77 of SEQ ID NO:6 consist of the corresponding residues from SEQ ID NO:3.

38. The method of claim 28, wherein said antagonist comprises amino acids 7 to 77 of SEQ ID NO:6.

39. The method of claim 28, wherein said
15 antagonist is administered to an endothelial cell.

40. The method of claim 28, wherein said one or more indicia of angiogenesis comprises altered cell migration.

20 41. The method of claim 28, wherein said one or more indicia of angiogenesis comprises altered cell survival.

42. The method of claim 28, wherein said one or more indicia of angiogenesis comprises altered cell
25 morphology.

43. The method of claim 28, wherein said antagonist is administered to a tissue.

44. The method of claim 43, wherein said tissue is any of cornea, chick chorioallantoic membrane and tumor tissue.

5 45. The method of claim 28, wherein said antagonist is administered to an animal.

46. The method of claim 45, wherein said animal is any of chicken, non-human primate, rat, mouse and human.

10 47. The method of claim 45, wherein said antagonist is administered to an animal having an angiogenesis-dependent disease.

48. The method of claim 47, wherein said angiogenesis-dependent disease is cancer.